Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Therapeutic potential of flavonoids in inflammatory bowel disease: A comprehensive review.

Salaritabar A, Darvishi B, Hadjiakhoondi F, Manayi A, Sureda A, Nabavi SF, Fitzpatrick LR, Nabavi SM, Bishayee A.

World J Gastroenterol. 2017 Jul 28;23(28):5097-5114. doi: 10.3748/wjg.v23.i28.5097. Review.

2.

A Novel Mathematical Model for Determining Faculty Workload.

Fitzpatrick LR, Millette-Snodgrass C, Atef E.

Am J Pharm Educ. 2016 Nov 25;80(9):152. doi: 10.5688/ajpe809152.

3.

The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice.

Fitzpatrick LR, Stonesifer E, Small JS, Liby KT.

Inflammopharmacology. 2014 Dec;22(6):341-9. doi: 10.1007/s10787-014-0203-2. Epub 2014 Apr 9.

PMID:
24715223
4.

Inflammation-induced functional connectivity of melanin-concentrating hormone and IL-10.

Ziogas DC, Karagiannis AK, Geiger BM, Gras-Miralles B, Najarian R, Reizes O, Fitzpatrick LR, Kokkotou E.

Peptides. 2014 May;55:58-64. doi: 10.1016/j.peptides.2014.02.005. Epub 2014 Feb 18.

5.

Probiotics for the treatment of Clostridium difficile associated disease.

Fitzpatrick LR.

World J Gastrointest Pathophysiol. 2013 Aug 15;4(3):47-52. doi: 10.4291/wjgp.v4.i3.47.

6.

Inhibition of IL-17 as a pharmacological approach for IBD.

Fitzpatrick LR.

Int Rev Immunol. 2013 Oct-Dec;32(5-6):544-55. doi: 10.3109/08830185.2013.821118. Epub 2013 Jul 25. Review.

PMID:
23886112
7.

Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice.

Fitzpatrick LR, Small JS, Greene WH, Karpa KD, Farmer S, Keller D.

Gut Pathog. 2012 Oct 22;4(1):13. doi: 10.1186/1757-4749-4-13.

8.

Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action.

Fitzpatrick LR, Small JS, Doblhofer R, Ammendola A.

J Pharmacol Exp Ther. 2012 Sep;342(3):850-60. doi: 10.1124/jpet.112.192203. Epub 2012 Jun 12.

PMID:
22691298
9.

Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis.

Fitzpatrick LR.

Int J Inflam. 2012;2012:389404. doi: 10.1155/2012/389404. Epub 2012 Mar 15.

10.

Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice.

Fitzpatrick LR, Small JS, Greene WH, Karpa KD, Keller D.

Gut Pathog. 2011 Oct 20;3(1):16. doi: 10.1186/1757-4749-3-16.

11.

Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2.

Fitzpatrick LR, Green C, Maines LW, Smith CD.

Pharmacology. 2011;87(3-4):135-43. doi: 10.1159/000323911. Epub 2011 Feb 22.

PMID:
21346391
12.

Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase.

Fitzpatrick LR, Green C, Frauenhoffer EE, French KJ, Zhuang Y, Maines LW, Upson JJ, Paul E, Donahue H, Mosher TJ, Smith CD.

Inflammopharmacology. 2011 Apr;19(2):75-87. doi: 10.1007/s10787-010-0060-6. Epub 2010 Oct 11.

PMID:
20936538
13.

4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.

Fitzpatrick LR, Deml L, Hofmann C, Small JS, Groeppel M, Hamm S, Lemstra S, Leban J, Ammendola A.

Inflamm Bowel Dis. 2010 Oct;16(10):1763-77. doi: 10.1002/ibd.21264.

PMID:
20310011
14.

Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease.

Maines LW, Fitzpatrick LR, Green CL, Zhuang Y, Smith CD.

Inflammopharmacology. 2010 Apr;18(2):73-85. doi: 10.1007/s10787-010-0032-x. Epub 2010 Feb 12.

PMID:
20151210
15.

A new model of chronic hapten-induced colitis in young rats.

Fitzpatrick LR, Meirelles K, Small JS, Puleo FJ, Koltun WA, Cooney RN.

J Pediatr Gastroenterol Nutr. 2010 Mar;50(3):240-50. doi: 10.1097/MPG.0b013e3181cb8f4a.

PMID:
20118800
16.

MEP1A allele for meprin A metalloprotease is a susceptibility gene for inflammatory bowel disease.

Banerjee S, Oneda B, Yap LM, Jewell DP, Matters GL, Fitzpatrick LR, Seibold F, Sterchi EE, Ahmad T, Lottaz D, Bond JS.

Mucosal Immunol. 2009 May;2(3):220-31. doi: 10.1038/mi.2009.3. Epub 2009 Mar 4.

18.

In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis.

Fitzpatrick LR, Small J, Hoerr RA, Bostwick EF, Maines L, Koltun WA.

Br J Nutr. 2008 Sep;100(3):530-41. doi: 10.1017/S0007114508930373. Epub 2008 Feb 18.

PMID:
18279557
19.

Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase.

Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN, Upson JJ, Smith CD.

Dig Dis Sci. 2008 Apr;53(4):997-1012. Epub 2007 Dec 4.

20.

Effects of the probiotic formulation VSL#3 on colitis in weanling rats.

Fitzpatrick LR, Hertzog KL, Quatse AL, Koltun WA, Small JS, Vrana K.

J Pediatr Gastroenterol Nutr. 2007 May;44(5):561-70.

PMID:
17460487
21.

Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease.

Fitzpatrick LR, Small JS, Poritz LS, McKenna KJ, Koltun WA.

Dis Colon Rectum. 2007 Mar;50(3):337-48; discussion 348-50.

PMID:
17160513
22.
23.
24.
25.
26.
27.
28.

Effect of naproxen on the hamster gastric antrum: ulceration, adaptation and efficacy of anti-ulcer drugs.

Fitzpatrick LR, Sakurai K, Le T.

Aliment Pharmacol Ther. 1999 Nov;13(11):1553-62.

29.

Indomethacin-induced gastric antral damage in hamsters: are neutrophils involved?

Fitzpatrick LR, Sakurai K, Le T.

Aliment Pharmacol Ther. 1999 Feb;13(2):195-202.

30.

RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat.

Pendley CE, Fitzpatrick LR, Capolino AJ, Davis MA, Esterline NJ, Jakubowska A, Bertrand P, Guyon C, Dubroeucq MC, Martin GE.

J Pharmacol Exp Ther. 1995 Jun;273(3):1015-22.

PMID:
7791071
31.
32.

Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.

Youssefyeh RD, Campbell HF, Klein S, Airey JE, Darkes P, Powers M, Schnapper M, Neuenschwander K, Fitzpatrick LR, Pendley CE, et al.

J Med Chem. 1992 Mar 6;35(5):895-903.

PMID:
1312602
33.

Acidic fibroblast growth factor accelerates the healing of acetic-acid-induced gastric ulcers in rats.

Fitzpatrick LR, Jakubowska A, Martin GE, Davis M, Jaye MC, Dionne CA.

Digestion. 1992;53(1-2):17-27.

PMID:
1283855
34.

Gastroprotective and ulcer healing profile of the mast cell stabilizer quazolast in rats.

Fitzpatrick LR, Decktor DL.

Agents Actions. 1991 Jul;33(3-4):330-6.

PMID:
1683105
35.
36.

RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.

Fitzpatrick LR, Lambert RM, Pendley CE, Martin GE, Bostwick JS, Gessner GW, Airey JE, Youssefyeh RD, Pendleton RG, Decktor DL.

J Pharmacol Exp Ther. 1990 Aug;254(2):450-5.

PMID:
2166791
37.

Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat.

Fitzpatrick LR, Bostwick JS, Renzetti M, Pendleton RG, Decktor DL.

Agents Actions. 1990 Jun;30(3-4):393-402.

PMID:
1974733
38.

Prostaglandin-mediated trophic effects on the rat duodenum: the role of polyamines.

Fitzpatrick LR, Gaginella TS, Haddox MK, Johnson LR.

Proc Soc Exp Biol Med. 1988 Nov;189(2):201-5.

PMID:
3143119
39.

Relationship between ornithine decarboxylase activity and gastric damage.

Thirumalai CH, Tseng CC, Tabata K, Fitzpatrick LR, Johnson LR.

Am J Physiol. 1987 Jul;253(1 Pt 1):G1-6.

PMID:
3111273
40.

Effect of epidermal growth factor on polyamine-synthesizing enzymes in rat enterocytes.

Fitzpatrick LR, Wang P, Johnson LR.

Am J Physiol. 1987 Feb;252(2 Pt 1):G209-14.

PMID:
3493704
41.

Effect of refeeding on polyamine biosynthesis in isolated enterocytes.

Fitzpatrick LR, Wang P, Eikenburg BE, Haddox MK, Johnson LR.

Am J Physiol. 1986 May;250(5 Pt 1):G709-13.

PMID:
3706530

Supplemental Content

Loading ...
Support Center